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Abstract: The field of chronobiology has vastly expanded over the past few decades, bringing 
together research from the fields of circadian rhythms and sleep. The importance of the envi-
ronmental day–night cycle on our health is becoming increasingly evident as we evolve into a 
24-hour society. Reducing or changing sleep times against our natural instincts to rest at night 
has a detrimental impact on our well-being. The mammalian circadian clock, termed “the 
suprachiasmatic nucleus”, is responsible for synchronizing our behavioral and physiological 
outputs to the environment. It utilizes light transcoded by specialized retinal photoreceptors as 
its cue to set internal rhythms to be in phase with the light–dark cycle. Misalignment of these 
outputs results in symptoms such as altered/disturbed sleep patterns, changes in mood, and 
physical and mental exhaustion – symptoms shared by many affective clinical disorders. Key 
links to circadian abnormalities have been found in a number of disorders, such as seasonal 
affective disorder, nonseasonal depression, and bipolar affective disorder. Furthermore, therapies 
developed through chronobiological research have been shown to be beneficial in the treatment 
of these conditions. In this article, we discuss the impact of circadian research on the manage-
ment of affective disorders, giving evidence of how a misaligned circadian system may be a 
contributor to the symptoms of depression and how moderating circadian rhythms with light 
therapy benefits patients.
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Introduction
Chronobiology is a vastly expanding field of research, incorporating both areas of 
circadian rhythms and sleep. Over the last decade, these two disciplines have become 
increasingly integrated, resulting in a better understanding of mechanisms that underpin 
both our physiological and behavioral daily routines. Consequently, these emerging 
principles are now being translated into the clinical setting and are proving to be fun-
damental, as the importance of both circadian rhythms and sleep in the preservation 
of human health is unraveled.
Through evolution, the environmental day–night cycle has been the predominant 
cue to which organisms have adapted their behavior. Humans have evolved into a 
diurnal species, preferring to sleep at night and restrict activity to the day. This daily 
pattern in synchronization has held true for centuries; however, modern society has 
begun to break away from this norm. With the advent of a “24-hour society”, we find 
ourselves paying less attention to our natural instincts to rest and rather favor socializing 
and working. Remarkably, many individuals turn to stimulants to prolong daily “active” 
duration in the pursuit of maximizing “awake” efficiency. However,  continually 





reducing the duration of rest or sleep is likely to be a key 
contributor to the “burnout” phenomenon, manifesting as 
extreme tiredness, mental exhaustion, and low mood. Thus, 
this cultural drift in day–night activity impacts negatively on 
our overall psychological well-being and health.
The synchronization of our daily behavior to the environ-
mental day–night cycle is governed by an inherent biological 
clock. This clock integrates light cues and our social signals to 
generate a harmonic balance between internal physiology and 
the outside world. However, a misalignment in such a system, 
due to either a self-driven motivation or a clinical disorder, 
can result in ill health.1 Recently, it has been shown that some 
of the characteristic symptoms of natural aging, for instance, 
abnormal sleep patterns, are likely to be a result of a circadian 
desynchronization.2 Complex neurological conditions such 
as affective disorders also share common symptoms that are 
suggestive of a deficit in circadian regulation. Treatments that 
are aimed at realigning or stabilizing physiological synchron-
icity with the environment have proven beneficial in seasonal 
affective disorder (SAD), nonseasonal depression, and bipolar 
affective disorders.3 In this article, we discuss and highlight 
the importance of chronobiology in affective disorders. In 
addition, we aim to show the impact of therapies devised from 
our current understanding of circadian biology to treat these 
conditions and their beneficial effect on patients.
The master clock and circadian 
entrainment
Mammals possess a master neuronal circadian pacemaker, 
the suprachiasmatic nucleus (SCN), which is situated within 
the anterior hypothalamus, beneath the third ventricle and 
above the optic chiasm.4 The SCN receives direct photic input 
from the eyes via the retinohypothalamic tract, providing 
vital information about the environmental day–night cycle. 
In addition, the SCN is also innervated by projections from 
the intergeniculate leaflet and raphe nucleus, which relay 
non-photic information, such as social and behavioral cues, 
to the clock.
Neurons of the SCN are endogenously rhythmic.5 These 
cells express circadian oscillations in both molecular gene 
expression of specific clock genes and in cellular electrical 
excitation.5,6 It is these rhythms that align themselves in 
response to photic and non-photic information received from 
afferent inputs. For instance, under a typical day–night cycle, 
the SCN displays increased electrical excitation during the 
day relative to the night.7 It is these outputs that will, in turn, 
provide a timing cue for other physiological systems, such 
as those governing sleep.
For humans, this synchronization presents itself through 
our preference to be active during the day and asleep at night. 
In addition, such synchronization can be modified by other 
neuronal systems governed by behavioral stimuli, such as 
social activities, meal times, and exercise. The incorporation 
of these behavioral signals and the light–dark cycle provides 
ultimate entrainment of an individual. For the purpose of this 
review, we will focus on aspects of circadian entrainment 
that have been identified to contribute to the mood disorders 
discussed in subsequent sections. For a detailed review on 
entrainment mechanisms, see Lall et al.8
Light input to the circadian clock
In mammals, light information enters the physiological system 
exclusively via the eye.9 This ocular detection of ambient light 
intensity, or irradiance, performs a significant role in circadian 
entrainment in addition to image-forming vision.10 When light 
reaches the retina, three classes of photoreceptor cells – rods, 
cones, and intrinsically photoreceptive retinal ganglion cells 
(ipRGCs) – decode and communicate photic information for 
further processing. For the purpose of visualization, rod and 
cone photoreceptors provide the core translational pathway; 
however, the task of circadian photoentrainment has been 
largely attributed to the subset of retinal ganglion cells pos-
sessing the novel photopigment melanopsin: the ipRGCs. For 
a detailed review on photoreceptor contribution to circadian 
entrainment, see Lucas et al.11
Light-evoked innervations from the combined actions 
of all classes of photoreceptor are signaled directly to the 
SCN via multisynaptic circuitry of the retinohypothalamic 
tract. These act to drive non-image-forming (NIF) responses 
of circadian photoentrainment, pupillary light reflex, pineal 
melatonin suppression, and sleep propensity.12–14 However, 
the communicated photic information is not defined simply 
by duration of light, as retinal sensitivity is subject to irradi-
ance and spectral composition.11,15 It has been shown experi-
mentally that the rod class of photoreceptor has the greatest 
sensitivity to light, with very low illumination still able to 
contribute to photoentrainment in the absence of other NIF 
responses.13,16,17 Under higher levels of irradiance, cones play 
a greater role in retinal decoding and, in turn, NIF responses, 
but essentially the melanopsin-containing ipRGCs provide 
the greatest contribution.13 Further, photoreceptor sensitiv-
ity has been demonstrated to vary according to wavelength 
of light.15 For melanopsin, peak sensitivity occurs around 
480 nm, suggesting lighting within the blue spectral range 
as being optimal for eliciting entraining photic cues.18–20 
Despite this class of photoreceptor being maximally sensitive 




Light therapy in affective disorders
to light and able to integrate ambient light levels throughout 
the duration of an entire day, it possesses very low sensitiv-
ity, requiring bright light for optimal signaling. Together, this 
has formed the basis of light therapy treatments typically 
comprising bright white or blue lights which are given during 
the day with the sole purpose of activating the melanopsin 
system and increasing photic signaling to the circadian clock, 
thus increasing the daylight signal to, in turn, drive circadian 
synchronization (entrainment).
Light as a therapeutic tool
A desynchronized circadian system results in significant 
changes in mood and sleep, such as those acutely experienced 
during jetlag. However, it is the presence of light that is able 
to drive the resynchronization of these systems through the 
SCN. Hence, this knowledge and understanding of the cir-
cadian system has led to the use of light in the treatment of 
psychiatric conditions that show symptoms of a destabilized 
clock. Bright bursts of light can act as strong signals to the 
SCN, thereby reinforcing daylight presence. Early controlled 
studies using bright light as a therapeutic tool for 3 hours 
in the morning and 3 hours in the evening during the  winter 
months proved an effective treatment for SAD “winter 
depression”, with the light stimulus acting to elongate the 
amount of daylight available throughout the day.21
Initially, light treatments for longer durations at lower inten-
sities (approximately 2,500 lux) were shown to be effective 
in eliciting an antidepressant response.21 However, increasing 
light intensity to 10,000 lux for 30–40 minutes yielded compa-
rable remission rates in subsequent SAD studies.22,23 In addition 
to intensity, spectral composition of light may be important. 
Typically polychromatic “white light” has shown greatest 
efficacy.21 However, following the discovery of melanopsin, 
light stimuli shifted toward the blue visual spectral range may 
be beneficial in achieving greater potency.24
In addition to discrete bursts of light, a paradigm simu-
lating the onset of dawn using illumination has also shown 
promise in the treatment of affective disorders. Such dawn 
simulation treatments are administered at the end of the night, 
lasting up to 2 hours in duration, during which environmental 
lighting is raised gradually from darkness to 250 lux, thus 
mimicking sunrise.25,26 Difficulty in awakening is often a 
common symptom found in SAD patients, and it is likely 
that dawn simulation acts to alleviate such symptoms by 
decreasing morning drowsiness.27–29 In addition, such treat-
ment has been shown to generate greater remission and 
response rates when compared against therapies involving 
a single pulse of bright light.30 Finally, it has been proposed 
that dawn simulation induces its effect by altering circadian 
phase in individuals.31
Adverse effects associated with light treatment are 
minimal. Several studies describe mild visual disturbances, 
including eyestrain and photophobia.21 Agitation, headaches, 
and eye irritations are reported across affective disorder 
trials;21 however, these are likely to be significantly minimized 
in dawn simulation paradigms. In a review of nonseasonal 
light therapy trials, the frequency of these symptoms was 
not shown to be significantly different from the control 
groups.32 In terms of ocular safety, a study of long-term 
exposure to light treatment did not reveal ophthalmological 
problems in participants.33,34 Overall, light therapy is consid-




Over the last few decades, research into both mammalian 
circadian rhythms and sleep has been rapidly progress-
ing, with a growing wealth of knowledge in the basic 
understanding of mechanisms that underlie each process. 
More recently, the realization of the importance of these 
findings in human health has been brought to the forefront. 
For example, the association between changes in various 
circadian rhythms and the occurrence of mood disorders has 
been extensively documented. Specifically, abnormalities 
in patterns in biochemical, neuroendocrine, physiologi-
cal, and behavioral outputs have been widely observed in 
patients suffering from affective disorders.35 In this sec-
tion, we will focus on the chronobiological significance 
and impact of light on seasonal, nonseasonal, and bipolar 
affective disorders.
Seasonal affective disorder
SAD is a clinical subtype of major depression, first defined 
in a seminal report by Rosenthal et al in 1984.28 SAD, or 
winter depression, presents in patients during the autumn 
and winter months with symptoms such as severe changes 
in mood, energy, and appetite.36 The seasonal dependence of 
SAD is strongly correlated with the decrease in daylight hours 
during symptomatic months. Conversely, as the day length 
increases, these symptoms are attenuated, leading to remis-
sion in the summer. The underlying mechanisms driving SAD 
have been associated with a deficit of the circadian system to 
adapt to the changing environment, predominately the light–
dark cycle. The precise workings remain unclear; however, 
a number of key candidates or pathways have been proposed, 





centering on the desynchronization of internal circadian-
driven physiology with the external environment.
In the first instance, changes in hormonal rhythms 
have been linked to SAD onset; of particular interest is the 
hormone melatonin, referred to as the “sleep hormone”. 
Melatonin levels typically rise at night and reach their lowest 
point during the day. The majority of circulating melatonin 
is produced by the pineal gland. The rhythmic profiling of 
melatonin is regulated, in part, by the light–dark cycle, as 
light acts to suppress production, thus driving the cyclic 
nature of this hormone.37 More significantly, the onset in 
expression of melatonin provides a strong biomarker for 
assessing circadian synchronization.38 Dim light melatonin 
onset (DLMO) is a useful indicator obtained by collection 
of sequential blood or saliva samples every 30–60 minutes, 
from early evening until bedtime, under dim light conditions. 
This marker provides an excellent output of internal physi-
ological entrainment when correlated to the environmental 
light–dark and sleep cycles.39
Sufferers of SAD exhibit a number of traits linked to this 
defined melatonin rhythm. Affected patients have been shown 
to express a delay in the DLMO coupled with a lengthened 
nocturnal and elevated secretion profile during the winter.40–43 
Due to the responsiveness of melatonin secretion to light, one 
of the major treatment strategies for SAD has centered on 
using light as a therapeutic agent. Bright light presented to 
patients during the morning or during both the morning and 
afternoon for around 3 hours resulted in significant remission 
rates in SAD individuals.21,28 The positive impact of light in 
the treatment of SAD is clear; however, its mode of action 
through adjustment of DLMO is still debatable, thus the 
antidepressant efficacy of light therapy cannot be defined 
by its effect on melatonin secretions alone.40,44,45 To this end, 
it has been proposed that light acts by resetting key internal 
rhythms governed by the circadian clock, thus realigning 
physiological phase to the environment.41,46
In addition to melatonin, the neurotransmitter serotonin 
(5-hydroxytryptamine [5-HT]) has been associated with 
modulation of behavior, emotion, and circadian rhythms.47 
Interestingly, hypothalamic serotonin concentrations 
investigated in postmortem samples revealed a distinctive 
seasonal pattern, with lower levels of serotonin detectable 
in the winter.48 In addition, there is a higher degradation of 
serotonin associated with light environments characteristic 
of winter months, and an amplified rate of serotonin produc-
tion in direct response to bright sunlight.49 Further, reduced 
brain serotonin levels share many similarities to SAD, for 
instance, carbohydrate craving, hyperphagia, hypersomnia, 
and attenuated melatonin levels.36 The role of serotonin in 
SAD is, however, uncertain. Acute reduction in serotonin 
levels in SAD patients remitting during the summer months 
has been shown to force sufferers into depressive relapse.50–52 
However, there is variability in the data, with other groups 
showing little or no effect.53,54 Depressive severities in SAD 
patients are also unaffected by indirect depletion of sero-
tonin levels.55,56 Together, these findings call into question 
the role and specificity of a disrupted serotonergic drive. 
Interestingly, SAD patients treated with pharmacological 
agents that increase serotonin together with light treatments 
did not respond significantly more than those using light 
alone; however, relapse rates in those taking the combina-
tion were slower.57
Nonseasonal depression
The association between nonseasonal depression and chro-
nobiology is one that is not made very often by clinicians or 
patients; however, there is accumulating evidence that has 
strengthened the link between circadian disruptions and the 
characteristic symptoms of nonseasonal depression. These 
include delayed sleep onset, non-restful sleep, early morn-
ing waking, daytime fatigue, and diurnal mood variation.35 
Typical treatments have focused predominantly on pharma-
cological interventions, mainly targeting the serotonergic 
pathways. The most commonly used are selective serotonin 
reuptake inhibitors (SSRIs), which act to increase endog-
enous levels of serotonin.
Having established commonalities among symptoms 
with SAD, the effectiveness of light treatment in nonseasonal 
depression has been investigated. Interestingly, therapeutic 
use of light in nonseasonal depressive individuals has shown 
optimal results at high intensities (.2,500 lux) scheduled to 
last between 30 minutes and 2 hours – a similar effect size 
to that observed in SAD patients.32,58 Further, the combina-
tion of light regimens with antidepressant compounds such 
as imipramine, sertraline, and citalopram has been shown 
to significantly improve mood, with faster response rates 
than an antidepressant-only control group.59–63 In addition, 
melatonin levels have also been found to show significant 
differences in patients with nonseasonal major depression 
when compared with healthy individuals.64 Due to the very 
nature of nonseasonal depression and its multifactorial causes 
and symptoms, a purely chronobiological light-driven treat-
ment regime would be difficult to apply. However, it is likely 
that some patients may benefit from those interventions that 
target specific circadian-related symptoms – if nothing else, 
to alleviate those patients specifically from their suffering.




Light therapy in affective disorders
Bipolar affective disorder
Bipolar affective disorder presents with a complex etiology 
and patients alternate between unpredictable mood states, 
typically between depression and normal affect or between 
depression and manic state.65 In general, behavioral therapies 
are used with caution in this population due to the unstable 
and temperamental nature of the disorder. However, patients 
have been found to respond to light treatments in a similar 
manner observed in a nonseasonal depressive group.47,65 
Chronotherapeutic strategies have included sleep deprivation 
in combination with light treatments to good effect, with rapid 
antidepressant responses observed, within 48 hours in some 
cases, which were sustained for a noteworthy 7 weeks.66,67 
However, light therapy in this population can result in a 
switch to mania or hypomania in response to treatment.58 
Thus, it is imperative that the use of light therapy is closely 
monitored to avoid such relapses. Currently, pharmacologi-
cal interventions show the greatest promise in the treatment 
of bipolar affective disorder, but therapies centered on 




A range of pharmacological agents have been utilized in 
the management of affective disorders, employing direct 
or indirect chronobiotic properties. Lithium, a mainstay 
psychopharmacological treatment in bipolar disorder, is 
known to consistently alter circadian phase of an individual.68 
 Melatonin formulations, such as Circadin®, and melatonin 
analogs, including ramelteon and tasimelteon, are found to be 
effective treatments in a range of insomnia disorders, but have 
not been studied extensively as antidepressant agents.69–71
Selective serotonin reuptake inhibitors (SSRIs) are widely 
used as first-line treatments in clinical practice for the treat-
ment of SAD and nonseasonal depression.72 The precise 
mechanism of action is debatable, but SSRIs influence the 
serotonergic system to improve overall mood.73 Interestingly, 
SSRIs have been found to alter circadian rhythms at both 
cellular and behavioral levels;74,75 hence, it is likely that some 
of the positive effects of SSRIs are through their regulation 
of the circadian system.
However, SSRI use is commonly associated with seri-
ous adverse effects, including reported gastrointestinal 
effects, weight changes, sexual dysfunction, and sleep 
 disturbances. Indeed, recent media attention has highlighted 
previously unrecognized side effects of SSRI use during 
pregnancy causing birth defects during development in 
utero.76  Moreover, SSRIs have a slow onset of action, thus 
it can be 2–8 weeks or more before a detectable therapeutic 
response is achieved. Consequently, it is not surprising that 
the adherence of patients to SSRIs is poor, with a recent 
study reporting 40%–50% failure during the maintenance 
period of treatment.77
Recently, a novel dual melatonergic and specif ic 
serotonergic antidepressant, agomelatine (Valdoxan), has 
shown potential in SAD patients.78 This compound aims 
to address both the abnormalities in the DLMO and the 
decrease in serotonin levels found in SAD. Agomelatine has 
been observed to demonstrate a rapid onset of action and 
effective symptomatic alleviation and offers a lower risk 
of relapse or discontinuation of symptoms in nonseasonal 
depressive individuals when compared to either a compara-
tor or placebo.
Conclusion
Research into circadian rhythms and sleep has opened up 
a whole new avenue in our understanding of many clini-
cal conditions. Of these, affective disorders appear to have 
aspects of circadian dysfunction that are clearly presented 
in their symptoms. However, the treatment regimes are not 
so clear-cut. Pharmacological interventions show potency, 
but can be hindered by undesirable side effects. Conversely, 
the use of light as a therapeutic aid shows great promise; 
coupled with potentially minimal or no unwanted side effects. 
It is imperative that we continue to work on optimizing such 
chronobiological interventions so as to fully realize their 
analeptic potential.
Disclosure
The authors report no conflicts of interest in this work or in 
any pharmacological interventions discussed.
References
1. Baron KG, Reid KJ. Circadian misalignment and health. Int Rev 
 Psychiatry. 2014;26(2):139–154.
2. Farajnia S, Deboer T, Rohling JH, Meijer JH, Michel S. Aging of the 
suprachiasmatic clock. Neuroscientist. 2014;20(1):44–55.
3. Asarnow LD, Soehner AM, Harvey AG. Basic sleep and circadian science 
as building blocks for behavioral interventions: a translational approach 
for mood disorders. Behav Neurosci. 2014;128(3):360–370.
4. Ralph MR, Lehman MN. Transplantation: a new tool in the analysis of 
the mammalian hypothalamic circadian pacemaker. Trends Neurosci. 
1991;14(8):362–366.
5. Brown TM, Piggins HD. Electrophysiology of the suprachiasmatic 
circadian clock. Prog Neurobiol. 2007;82(5):229–255.
6. Reppert SM, Weaver DR. Molecular analysis of mammalian circadian 
rhythms. Annu Rev Physiol. 2001;63:647–676.
7. Shibata S, Oomura Y, Kita H, Hattori K. Circadian rhythmic changes of 
neuronal activity in the suprachiasmatic nucleus of the rat hypothalamic 
slice. Brain Res. 1982;247(1):154–158.





 8. Lall GS, Atkinson LA, Corlett SA, Broadbridge PJ, Bonsall DR. 
 Circadian entrainment and its role in depression: a mechanistic review. 
J Neural Transm. 2012;119(10):1085–1096.
 9. Foster RG. Shedding light on the biological clock. Neuron. 
1998;20(5):829–832.
 10. Lucas RJ, Foster RG. Neither functional rod photoreceptors nor rod 
or cone outer segments are required for the photic inhibition of pineal 
melatonin. Endocrinology. 1999;140(4):1520–1524.
 11. Lucas RJ, Lall GS, Allen AE, Brown TM. How rod, cone, and melanop-
sin photoreceptors come together to enlighten the mammalian circadian 
clock. Prog Brain Res. 2012;199:1–18.
 12. Güler AD, Ecker JL, Lall GS, et al. Melanopsin cells are the principal 
conduits for rod-cone input to non-image-forming vision. Nature. 
2008;453(7191):102–105.
 13. Lall GS, Revell VL, Momiji H, et al. Distinct contributions of rod, 
cone, and melanopsin photoreceptors to encoding irradiance. Neuron. 
2010;66(3):417–428.
 14. Peirson SN, Halford S, Foster RG. The evolution of irradiance  detection: 
melanopsin and the non-visual opsins. Philos Trans R Soc Lond B Biol 
Sci. 2009;364(1531):2849–2865.
 15. Enezi J, Revell V, Brown T, Wynne J, Schlangen L, Lucas R. 
A “melanopic” spectral efficiency function predicts the sensitivity of 
melanopsin photoreceptors to polychromatic lights. J Biol Rhythms. 
2011;26(4):314–323.
 16. Altimus CM, Güler AD, Alam NM, et al. Rod photoreceptors drive 
circadian photoentrainment across a wide range of light intensities. 
Nat Neurosci. 2010;13(9):1107–1112.
 17. Butler MP, Silver R. Divergent photic thresholds in the non-image-
forming visual system: entrainment, masking and pupillary light reflex. 
Proc Biol Sci. 2011;278(1706):745–750.
 18. Hattar S, Lucas RJ, Mrosovsky N, et al. Melanopsin and rod-cone pho-
toreceptive systems account for all major accessory visual functions in 
mice. Nature. 2003;424(6944):76–81.
 19. Lucas RJ, Douglas RH, Foster RG. Characterization of an ocular 
photopigment capable of driving pupillary constriction in mice. Nat 
Neurosci. 2001;4(6):621–626.
 20. Rollag MD, Berson DM, Provencio I. Melanopsin, ganglion-cell 
photoreceptors, and mammalian photoentrainment. J Biol Rhythms. 
2003;18(3):227–234.
 21. Terman M, Terman JS. Light therapy for seasonal and nonseasonal 
depression: efficacy, protocol, safety, and side effects. CNS Spectr. 
2005;10(8):647–663; quiz 672.
 22. Magnusson A, Kristbjarnarson H. Treatment of seasonal affective dis-
order with high-intensity light. A phototherapy study with an Icelandic 
group of patients. J Affect Disord. 1991;21(2):141–147.
 23. Terman JS, Terman M, Schlager D, et al. Efficacy of brief, intense light 
exposure for treatment of winter depression. Psychopharmacol Bull. 
1990;26(1):3–11.
 24. Meesters Y, Dekker V, Schlangen LJ, Bos EH, Ruiter MJ. Low-intensity 
blue-enriched white light (750 lux) and standard bright light (10,000 
lux) are equally effective in treating SAD. A randomized controlled 
study. BMC Psychiatry. 2011;11:17.
 25. Avery DH, Bolte MA, Dager SR, et al. Dawn simulation treatment of 
winter depression: a controlled study. Am J Psychiatry. 1993;150(1): 
113–117.
 26. Terman M, Terman JS. Controlled trial of naturalistic dawn simula-
tion and negative air ionization for seasonal affective disorder. Am J 
Psychiatry. 2006;163(12):2126–2133.
 27. Avery DH, Kouri ME, Monaghan K, Bolte MA, Hellekson C, Eder D. 
Is dawn simulation effective in ameliorating the difficulty awakening 
in seasonal affective disorder associated with hypersomnia? J Affect 
Disord. 2002;69(1–3):231–236.
 28. Rosenthal NE, Sack DA, Gillin JC, et al. Seasonal affective disorder. 
A description of the syndrome and preliminary findings with light 
therapy. Arch Gen Psychiatry. 1984;41(1):72–80.
 29. Rosenthal NE. Diagnosis and treatment of seasonal affective disorder. 
JAMA. 1993;270(22):2717–2720.
 30. Avery DH, Eder DN, Bolte MA, et al. Dawn simulation and bright 
light in the treatment of SAD: a controlled study. Biol Psychiatry. 
2001;50(3):205–216.
 31. Terman M, Terman JS. Circadian rhythm phase advance with 
dawn simulation treatment for winter depression. J Biol Rhythms. 
2010;25(4):297–301.
 32. Tuunainen A, Kripke DF, Endo T. Light therapy for non-seasonal 
depression. Cochrane Database Syst Rev. 2004;(2):CD004050.
 33. Even C, Schröder CM, Friedman S, Rouillon F. Efficacy of light 
therapy in nonseasonal depression: a systematic review. J Affect Disord. 
2008;108(1–2):11–23.
 34. Gallin PF, Terman M, Remé CE, Rafferty B, Terman JS, Burde RM. 
Ophthalmologic examination of patients with seasonal affective 
disorder, before and after bright light therapy. Am J Ophthalmol. 
1995;119(2):202–210.
 35. Germain A, Kupfer DJ. Circadian rhythm disturbances in depression. 
Hum Psychopharmacol. 2008;23(7):571–585.
 36. Miller AL. Epidemiology, etiology, and natural treatment of seasonal 
affective disorder. Altern Med Rev. 2005;10(1):5–13.
 37. Pandi-Perumal SR, Trakht I, Srinivasan V, et al. Physiological effects of 
melatonin: role of melatonin receptors and signal transduction pathways. 
Prog Neurobiol. 2008;85(3):335–353.
 38. Pandi-Perumal SR, Srinivasan V, Maestroni GJ, Cardinali DP, Poeggeler B, 
Hardeland R. Melatonin: nature’s most versatile biological signal? 
FEBS J. 2006;273(13):2813–2838.
 39. Hickie IB, Rogers NL. Novel melatonin-based therapies: potential 
advances in the treatment of major depression. Lancet. 2011;378(9791): 
621–631.
 40. Rice J, Mayor J, Tucker HA, Bielski RJ. Effect of light therapy on 
salivary melatonin in seasonal affective disorder. Psychiatry Res. 
1995;56(3):221–228.
 41. Lewy AJ, Sack RL, Miller LS, Hoban TM. Antidepressant and circadian 
phase-shifting effects of light. Science. 1987;235(4786):352–354.
 42. Wehr TA, Duncan WC Jr, Sher L, et al. A circadian signal of change of 
season in patients with seasonal affective disorder. Arch Gen Psychiatry. 
2001;58(12):1108–1114.
 43. Danilenko KV, Putilov AA, Russkikh GS, Duffy LK, Ebbesson SO. 
 Diurnal and seasonal variations of melatonin and serotonin in women with 
seasonal affective disorder. Arctic Med Res. 1994;53(3):137–145.
 44. Murphy DG, Murphy DM, Abbas M, et al. Seasonal affective disorder: 
response to light as measured by electroencephalogram, melatonin sup-
pression, and cerebral blood flow. Br J Psychiatry. 1993;163:327–331, 
335–327.
 45. Partonen T, Vakkuri O, Lönnqvist J. Suppression of melatonin secre-
tion by bright light in seasonal affective disorder. Biol Psychiatry. 
1997;42(6):509–513.
 46. Lewy AJ. Circadian misalignment in mood disturbances. Curr 
Psychiatry Rep. 2009;11(6):459–465.
 47. Pail G, Huf W, Pjrek E, et al. Bright-light therapy in the treatment of 
mood disorders. Neuropsychobiology. 2011;64(3):152–162.
 48. Carlsson A, Svennerholm L, Winblad B. Seasonal and circadian 
monoamine variations in human brains examined post mortem. Acta 
Psychiatr Scand Suppl. 1980;280:75–85.
 49. Lambert GW, Reid C, Kaye DM, Jennings GL, Esler MD. Effect 
of sunlight and season on serotonin turnover in the brain. Lancet. 
2002;360(9348):1840–1842.
 50. Neumeister A, Praschak-Rieder N, Hesselmann B, et al. Effects of 
tryptophan depletion in fully remitted patients with seasonal affective 
disorder during summer. Psychol Med. 1998;28(2):257–264.
 51. Neumeister A, Turner EH, Matthews JR, et al. Effects of tryptophan 
depletion vs catecholamine depletion in patients with seasonal affec-
tive disorder in remission with light therapy. Arch Gen Psychiatry. 
1998;55(6):524–530.
 52. Lam RW, Zis AP, Grewal A, Delgado PL, Charney DS, Krystal JH. 
Effects of rapid tryptophan depletion in patients with seasonal affec-
tive disorder in remission after light therapy. Arch Gen Psychiatry. 
1996;53(1):41–44.
ChronoPhysiology and herapy
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/chronophysiology-and-therapy-journal
ChronoPhysiology and Therapy is an international, peer-reviewed, 
open access journal focusing on research into the cyclic variations and 
rhythmicity in physiological processes in the body and the research and 
development and optimal timing of administration of therapeutic targets 
to achieve improved outcomes and quality of life for the patient. The 
manuscript management system is completely online and includes a 
very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.





Light therapy in affective disorders
 53. Neumeister A, Praschak-Rieder N, Hesselmann B, et al. Effects of 
tryptophan depletion in drug-free depressed patients who responded 
to total sleep deprivation. Arch Gen Psychiatry. 1998;55(2):167–172.
 54. Lam RW, Bowering TA, Tam EM, et al. Effects of rapid tryptophan 
depletion in patients with seasonal affective disorder in natural summer 
remission. Psychol Med. 2000;30(1):79–87.
 55. Neumeister A, Praschak-Rieder N, Hesselmann B, et al. Rapid trypto-
phan depletion in drug-free depressed patients with seasonal affective 
disorder. Am J Psychiatry. 1997;154(8):1153–1155.
 56. Partonen T, Lönnqvist J. Seasonal affective disorder. Lancet. 
1998;352(9137):1369–1374.
 57. McGrath RE, Buckwald B, Resnick EV. The effect of L-tryptophan on 
seasonal affective disorder. J Clin Psychiatry. 1990;51(4):162–163.
 58. Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy 
in the treatment of mood disorders: a review and meta-analysis of the 
evidence. Am J Psychiatry. 2005;162(4):656–662.
 59. Holsboer-Trachsler E, Hemmeter U, Hatzinger M, Seifritz E, Gerhard U, 
Hobi V. Sleep deprivation and bright light as potential augmenters 
of antidepressant drug treatment – neurobiological and psychometric 
assessment of course. J Psychiatr Res. 1994;28(4):381–399.
 60. Martiny K, Lunde M, Undén M, Dam H, Bech P. Adjunctive bright 
light in non-seasonal major depression: results from clinician-rated 
depression scales. Acta Psychiatr Scand. 2005;112(2):117–125.
 61. Beauchemin KM, Hays P. Phototherapy is a useful adjunct in the treatment 
of depressed in-patients. Acta Psychiatr Scand. 1997;95(5):424–427.
 62. Loving RT, Kripke DF, Shuchter SR. Bright light augments antide-
pressant effects of medication and wake therapy. Depress Anxiety. 
2002;16(1):1–3.
 63. Benedetti F, Terman M. Much ado about … a moody clock. Biol 
 Psychiatry. 2013;74(4):236–237.
 64. Buckley TM, Schatzberg AF. A pilot study of the phase angle between 
cortisol and melatonin in major depression – a potential biomarker? 
J Psychiatr Res. 2010;44(2):69–74.
 65. Deltito JA, Moline M, Pollak C, Martin LY, Maremmani I. Effects of 
phototherapy on non-seasonal unipolar and bipolar depressive spectrum 
disorders. J Affect Disord. 1991;23(4):231–237.
 66. Wu JC, Kelsoe JR, Schachat C, et al. Rapid and sustained antidepressant 
response with sleep deprivation and chronotherapy in bipolar disorder. 
Biol Psychiatry. 2009;66(3):298–301.
 67. Benedetti F, Barbini B, Fulgosi MC, et al. Combined total sleep 
deprivation and light therapy in the treatment of drug-resistant bipo-
lar depression: acute response and long-term remission rates. J Clin 
 Psychiatry. 2005;66(12):1535–1540.
 68. Klemfuss H. Rhythms and the pharmacology of lithium. Pharmacology 
Ther. 1992;56(1):53–78.
 69. Lemoine P, Zisapel N. Prolonged-release formulation of melatonin 
(Circadin) for the treatment of insomnia. Expert Opin Pharmacother. 
2012;13(6):895–905.
 70. Kawabe K, Horiuchi F, Oka Y, Ueno S. The melatonin receptor agonist 
ramelteon effectively treats insomnia and behavioral symptoms in 
autistic disorder. Case Rep Psychiatry. 2014;2014:561071.
 71. Hardeland R. Tasimelteon, a melatonin agonist for the treatment of 
insomnia and circadian rhythm sleep disorders. Curr Opin Investig 
Drugs. 2009;10(7):691–701.
 72. NICE. Depression: the treatment and management of depression in 
adults (update). National Institute for Health and Clinical Excellence; 
2009;CG23. Available from http://www.nice.org.uk/guidance/cg90/
resources/guidance-depression-in-adults-pdf. Accessed September 11, 
2014.
 73. Coplan JD, Gopinath S, Abdallah CG, Berry BR. A neurobiological 
hypothesis of treatment-resistant depression – mechanisms for selec-
tive serotonin reuptake inhibitor non-efficacy. Front Behav Neurosci. 
2014;8:189.
 74. Sprouse J, Braselton J, Reynolds L. Fluoxetine modulates the circadian 
biological clock via phase advances of suprachiasmatic nucleus neuronal 
firing. Biol Psychiatry. 2006;60(8):896–899.
 75. Westrich L, Sprouse J, Sánchez C. The effects of combining serotonin 
reuptake inhibition and 5-HT7 receptor blockade on circadian rhythm 
regulation in rodents. Physiol Behav. 2013;110–111:42–50.
 76. Kepser LJ, Homberg JR. The neurodevelopmental effects of serotonin: 
a behavioural perspective. Behav Brain Res. Epub May 23, 2014.
 77. López-Torres J, Párraga I, Del Campo JM, Villena A; ADSCAMFYC 
Group. Follow up of patients who start treatment with antidepressants: 
treatment satisfaction, treatment compliance, efficacy and safety. BMC 
Psychiatry. 2013;13:65.
 78. Pjrek E, Winkler D, Konstantinidis A, Willeit M, Praschak-Rieder N, 
Kasper S. Agomelatine in the treatment of seasonal affective disorder. 
Psychopharmacology (Berl). 2007;190(4):575–579.
